WO2010057985A2 - Vaccin marqueur de la salmonelle - Google Patents

Vaccin marqueur de la salmonelle Download PDF

Info

Publication number
WO2010057985A2
WO2010057985A2 PCT/EP2009/065571 EP2009065571W WO2010057985A2 WO 2010057985 A2 WO2010057985 A2 WO 2010057985A2 EP 2009065571 W EP2009065571 W EP 2009065571W WO 2010057985 A2 WO2010057985 A2 WO 2010057985A2
Authority
WO
WIPO (PCT)
Prior art keywords
phon
salmonella
strain
seq
vaccine
Prior art date
Application number
PCT/EP2009/065571
Other languages
English (en)
Other versions
WO2010057985A3 (fr
Inventor
Heiko Apfel
Original Assignee
Creatogen Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creatogen Laboratories Gmbh filed Critical Creatogen Laboratories Gmbh
Priority to BRPI0921065A priority Critical patent/BRPI0921065A2/pt
Priority to EP09753133A priority patent/EP2358384A2/fr
Priority to MX2011005281A priority patent/MX2011005281A/es
Priority to JP2011536877A priority patent/JP2012509075A/ja
Priority to CN2009801527921A priority patent/CN102361648A/zh
Priority to AU2009317211A priority patent/AU2009317211A1/en
Priority to CA2744251A priority patent/CA2744251A1/fr
Priority to US13/129,844 priority patent/US20120114698A1/en
Publication of WO2010057985A2 publication Critical patent/WO2010057985A2/fr
Publication of WO2010057985A3 publication Critical patent/WO2010057985A3/fr
Priority to ZA2011/04477A priority patent/ZA201104477B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a Salmonella strain having an inactivated phoN gene.
  • the invention relates to a method for the preparation of AphoN Salmonella enterica live-attenuated vaccine strains.
  • the invention relates to a serological test system which uses the recombinant Salmonella protein PhoN for discrimination of vaccinated animals from Salmonella infected ones. Furthermore a bacteriological test system is disclosed for DIVA.
  • the invention further concerns the Salmonella enterica ssp. enterica serovar Enteritidis strain CLAB SE404 (DSM 21972) and its use as a live-attenuated AphoN Salmonella marker vaccine strain for the treatment of poultry to prevent Salmonella Enteritidis infection and/or for the preparation of polyvalent recombinant Salmonella carrier vaccines which protect livestock against additional pathogens.
  • CLAB SE404 enables the Differentiation of infected from Vaccinated Animals (DIVA) by serological or/and bacteriological means.
  • Nontyphoidal Salmonellosis is a widespread disease in animals and humans. In men it is the most common food-borne disease which mainly originates from products of poultry and pigs. In the European Union a surveillance system will be established which should reduce the intake of pathogenic Salmonella ssp. into the food chain (regulation EC 2160/2003). Vaccination may reduce the prevalence of pathogenic Salmonella ssp. in livestock and thus minimize the transmission rate.
  • Anil-Salmonella vaccines are commercially available e.g. for laying hens and pigs. The vaccines are either bacterins or live-attenuated Salmonella vaccines. In laying hens, these vaccines are used to reduce intra-ovarian transmission and fecal shedding of the pathogen.
  • the efficacy of live-attenuated Salmonella vaccines has been found superior to bacterins.
  • DIVA Differentiation of infected from Vaccinated Animals
  • live-attenuated Salmonella vaccines are prepared from defined wildtype isolates of Salmonella enterica ssp. enterica serovars by chemical mutagenesis.
  • live-attenuated Salmonella vaccines are distinguished from wildtype Salmonella ssp. by bacteriological means. These processes are long lasting and laborious. A serological discrimination of vaccinated and infected animals would be highly preferable.
  • the presently available live-attenuated Salmonella vaccines do not enable a serological discrimination according to DIVA strategy.
  • DIVA live vaccines have been successfully used in livestock for the prevention of viral infections.
  • a marker vaccine can be prepared either as positive or negative marker.
  • a positive marker vaccine contains an additional antigen which induces specific antibodies in vaccinated animals but not in infected ones. Positive marker vaccines are clearly disadvantageous because vaccinated animals with a subsequent infection cannot be discriminated from solely vaccinated ones.
  • a negative marker vaccine is prepared by removal of an antigen which provokes specific antibodies in infected animals.
  • a negative marker vaccine provokes a humoral immune response in vaccinated animals that is different from that of infected animals. Ideally, this difference can be detected by serological means.
  • a negative marker vaccine enables the identification of vaccinated animals which become subsequently infected.
  • the antigen must be immunogenic but not be involved in the immune processes which protect animals against the pathogen. Thus the removal or inactivation of the gene which encodes the marker antigen must maintain immunogenicity of the vaccine strain. Finally, the marker antigen should be specific for the pathogen in order to avoid false-positive serological results which are induced by other organisms that may appear in livestock and provoke a humoral immune response.
  • Live-attenuated bacterial marker vaccines are still at an experimental stage.
  • the first candidates of a negative Salmonella marker vaccine were established from live-attenuated Salmonella vaccine strains by deleting the genes of highly immunogenic surface antigens.
  • These live-attenuated Salmonella DIVA vaccines were able to differentiate infected from vaccinated animals by serological means. However, these prototypes were less protective than the parental vaccine strain.
  • the gene phoN encodes a non-specific acid phosphatase, which has been found widely preserved in all Salmonella ssp.
  • the gene phoN is expressed under the control of the PhoPQ regulon, which is a general regulator for virulence genes in Salmonella. It is not known whether phoN is essential for the survival of Salmonella in animals.
  • the linkage of phoN to the PhoPQ regulon may indicate that phoN becomes activated whenever Salmonella occupies the host's tissue.
  • the question remains whether the elimination or inactivation of the gene phoN in a live- attenuated Salmonella vaccine strain may negatively affect its potential to induce protective immunity in vaccinated animals. It is known that the depletion of a single gene in a live-attenuated Salmonella vaccine strain may further reduce its residual virulence which may diminish the stimulation of the host's immune response and as a consequence may abrogate protective immunity.
  • the gene phoN has been selected as a target for the preparation of a Salmonella DIVA vaccine.
  • the phoN gene provides a combination of properties that make a p/7 ⁇ /-deficient Salmonella strain especially suitable as a live vaccine.
  • the first surprising property is the different structure of the PhoN protein in all non-Salmonella bacteria compared with Salmonella.
  • the PhoN amino acid sequence has a degree of at least 95 % identity (calculated over the total length of the amino acid sequence) in different Salmonella species.
  • PhoN is immunogenic. Analyses of sera from chicken and mice infected with Salmonella ssp. clearly revealed the appearance of antibodies which specifically bind to purified PhoN protein. This result provides the first evidence that PhoN is immunogenic and can be used as serological marker antigen for detecting Sa//77one//a-infected birds and mammals. If the expression of the gene phoN is abolished in any Salmonella vaccine strain, this might allow the discrimination of infected animals from vaccinated ones by serological means. Thus, animals vaccinated by a Salmonella live vaccine strain with depleted PhoN antigen, will not produce P ⁇ o/V-specific antibodies, whilst animals which become infected with wildtype Salmonella would do so.
  • the third surprising property is the fact that the removal of the gene phoN of a live-attenuated Salmonella vaccine strain may further reduce the virulence of the vaccine strain but does not affect its immunogenicity and its efficacy to protect vaccinated chicken from Salmonella infection of homologous serovar.
  • a first subject of the present invention is a Salmonella strain having an inactivated phoN gene. This in indicated herein by AphoN.
  • a AphoN Salmonella strain has essentially no phoN activity. The person skilled in molecular biology knows methods of gene inactivation in bacteria such as Salmonella.
  • Inactivation of phoN includes deletion or/and modification of the phoN gene.
  • the Salmonella strain of the present invention produces essentially no PhoN protein or a fragment thereof which is capable to induce an immune response against the PhoN protein or a fragment thereof, i.e. the Salmonella strain of the present invention is not immunogenic with respect to the PhoN protein or a fragment thereof.
  • the phoN gene may be deleted completely or at least partially. Partial deletion of the phoN gene may be a deletion of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, or at least 98% of the full-length sequence of the phoN gene. If the phoN gene sequence is deleted partially, the remaining sequences are preferably not be able to express a PhoN protein or a fragment thereof, in particular an immunogenic fragment as described herein.
  • Modification of the phoN gene sequence includes sequence replacement.
  • the phoN gene may be completely replaced by another sequence.
  • Deleted sequences of the phoN gene may be replaced completely or partially by other sequences.
  • the coding sequence (open reading frame) of the phoN gene may be deleted completely or at least partially. Partial deletion of the phoN coding sequence may be a deletion of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, or at least 98% of the sequence of the full-length phoN coding sequence. If the phoN coding sequence is deleted partially, the remaining sequences are preferably not be able to express a PhoN protein or a fragment thereof, in particular an immunogenic fragment as described herein.
  • Modification of the phoN coding sequence includes sequence replacement.
  • the phoN coding sequence may be completely replaced by another sequence.
  • Deleted sequences of the phoN coding sequence may be replaced completely or partially by other sequences.
  • Typical examples of sequence of the phoN polypeptide in Salmonella are described in Fig. 1 (SEQ ID NO:1 to 20).
  • Typical examples of the Salmonella phoN gene locus are described in Fig. 2 including the phoN open reading frames (ORF) and regulatory sequences upstream or/and downstream of the phoN ORF (SEQ ID NO:23 to 27).
  • Fragments of the phoN polypeptide of the present invention may have a length of a least 10, at least 20, or at least 30 amino acid residues. They may have a length of at the maximum 200, at the maximum 150, or at the maximum 100 amino acid residues. Fragments include immunogenic fragments (also termed herein as immunogenic portions).
  • Inactivation of the phoN gene is preferably irreversible inactivation, such as by complete or at least partial deletion of the phoN coding region, or by replacement of the phoN coding region, as described herein.
  • irreversible inactivation prevents the Salmonella strain of the present invention from reverting to the wildtype phoN genotype.
  • the Salmonella strain of the present invention produces essentially no PhoN protein which is capable to induce an immune response against the PhoN protein, i.e. the Salmonella strain of the present invention is not immunogenic with respect to the PhoN protein or a fragment thereof.
  • lmmunogenicity with respect to the PhoN protein or a fragment thereof may be an immunogenicity in any species to be treated with the Salmonella strain of the present invention.
  • immunogenicity with respect to the PhoN protein or a fragment thereof is immunogenicity in mammals, e.g. pigs, or birds, e.g. poultry such as chickens.
  • the Salmonella PhoN protein may be a protein comprising a sequence selected from SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 , SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, or a polypeptide comprising a sequence which is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the selected sequence, wherein identity is calculated relative to the length of the
  • a non-Salmonella PhoN protein may be a PhoN protein obtained from Escherichia or Shigella and may have a sequence selected from SEQ ID NO:21 and SEQ ID NO:22, or a polypeptide comprising a sequence which is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NO:21 and SEQ ID NO:22, wherein identity is calculated relative to the length of the selected sequence.
  • the Salmonella strain which is subject to phoN inactivation as described herein in order to obtain a strain according to the present invention may be selected from Salmonella enterica ssp. It is preferred that the Salmonella strain is selected from serovars of Salmonella enterica ssp. enterica, for example from serovar Enteritidis, Dublin, Gallinarum, Typhimurium, Newport, Choleraesuis, Agona, Hadar, Heidelberg, Kentucky, Saintpaul, Virchow, Weltevreden, Javiana, Schwarzengrund, Paratyphi, and Typhi, or from the serovars listed in Figure 1.
  • the Salmonella strain which is subject to phoN inactivation as described herein may be an attenuated Salmonella strain, for example a live- attenuated Salmonella strain, for example a live-attenuated Salmonella enterica ssp. enterica serovar Enteritidis His " Ade ⁇ strain such as the strain Salmovac SE (Springer et al., 2000, Berl. Munch. Tier GmbHl. Wschr. 113, 246-252) or a variant thereof.
  • Inactivation of the phoN gene as described herein may also be applied to authorized live-attenuated Salmonella vaccines. These strains may be transformed into live-attenuated Salmonella ⁇ phoN marker vaccines without affecting their immunogenicity in order to protect livestock e.g. from Salmonella infection and to simultaneously allow the discrimination of vaccinated from Salmonella infected livestock.
  • This transformation method can be applied for live-attenuated Salmonella vaccine strains which have been prepared by chemical mutagenesis and/or genetic engineering, or for any recombinant Salmonella vaccine approach which uses the live- attenuated Salmonella vaccine strain for example as a carrier to express at least one additional autologous antigen and/or one additional antigen of a heterologous pathogen, or for live-attenuated Salmonella vaccine strain used as a carrier to deliver DNA for vaccination.
  • Salmonella strain which is subject to phoN inactivation as described herein being a live-attenuated Salmonella vaccine strain is in particular (i) a vaccine strain prepared by chemical mutagenesis and/or genetic engineering,
  • a recombinant vaccine strain which optionally recombinantly expresses at least one autologous Salmonella antigen and/or at least one heterologous antigen, e.g. an antigen of a heterologous pathogen, or
  • a preferred Salmonella strain of the present invention is Salmonella enterica enterica Enteritidis strain CLAB SE404 (DSM 21972), and any strain derived therefrom.
  • the Salmonella strain of the present invention strain may be for use in medicine, e.g. in veterinary medicine.
  • the Salmonella strain of the present invention, in particular strain DSM 21972 may be for use as a vaccine.
  • the Salmonella strain of the present invention, in particular strain DSM 21972 may be for use as a live vaccine.
  • the Salmonella strain of the present invention, in particular the vaccine as described herein, more particular strain DSM 21972, may be for use as a vaccine to protect against a Salmonella infection, in particular against an infection with Salmonella enterica ssp.
  • the Salmonella strain of the present invention, in particular strain DSM 21972 may be for use in mammals, e.g. pigs, or birds, e.g. poultry such as chickens.
  • the Salmonella strain of the present invention strain may be used for the manufacture of a medicament, e.g. a medicament in veterinary medicine.
  • the Salmonella strain of the present invention, in particular strain DSM 21972 may be used for the manufacture of a vaccine.
  • the Salmonella strain of the present invention, in particular strain DSM 21972 may be used for the manufacture of a live vaccine.
  • the Salmonella strain of the present invention, in particular the vaccine as described herein, more in particular strain DSM 21972 may be used for the manufacture of a vaccine to protect against a Salmonella infection, in particular against an infection with Salmonella enterica ssp.
  • the Salmonella strain of the present invention, in particular strain DSM 21972 may used for the manufacture of a medicament for use in mammals, e.g. pigs, or birds, e.g. poultry such as chickens.
  • the vaccine of the present invention in particular strain DSM 21972, may be a vaccine to protect against subsequent Salmonella infection, in particular against a subsequent infection with Salmonella enterica ssp., and to prepare polyvalent recombinant Salmonella carrier vaccines which protect against additional pathogens.
  • the vaccine optionally recombinantly expresses at least one autologous Salmonella antigen and/or at least one heterologous antigen, e.g. an antigen of a heterologous pathogen.
  • the vaccine may be suitable for administration to a mammal, e.g. a pig, or birds, e.g. poultry such as chickens.
  • Subject of the present invention is a method for prevention or/and treatment of a Salmonella infection comprising administration of a Salmonella strain of the present invention, in particular strain DSM 21972, to a subject in need thereof.
  • the subject may be a mammal, e.g. a pig, or birds, e.g. poultry such as chickens.
  • a further subject of the present invention is a method of prevention or/and treatment of an infection with a pathogen comprising administration of a Salmonella strain of the present invention to a subject in need thereof, wherein the Salmonella strain of the present invention is prepared to confer protection against this pathogen, for instance a polyvalent Salmonella live vaccine.
  • this Salmonella strain is derived from DSM 21972.
  • the subject may be a mammal, e.g. a pig, or birds, e.g. poultry such as chickens.
  • the pathogen is different from Salmonella.
  • Yet another subject of the present invention is a method for production of Salmonella strain as described herein, in particular strain DSM 21972, comprising inactivating the phoN gene of a Salmonella strain.
  • inactivation of phoN may further reduce the virulence of a live-attenuated Salmonella vaccine strain, but it does not affect the immunogenicity of that transformed Salmonella vaccine strain. Therefore phoN inactivation is a suitable method to produce live-attenuated Salmonella DIVA vaccine strains.
  • the preparation of a live-attenuated AphoN Salmonella DIVA vaccine may start from any live-attenuated Salmonella vaccine strain which is able to protect for instance avian and/or mammal livestock against a Salmonella infection, in particular against an infection with Salmonella enterica ssp.
  • the preparation of DSM 21972 started from a variant of strain Salmovac SE. From such a Salmonella vaccine strain the gene phoN is inactivated as described herein by applying genetic engineering. After completion of the inactivation of phoN, the individual Salmonella variant strains have to be analyzed in order to evaluate differences which appear in relation to the parental Salmonella vaccine strain.
  • the AphoN Salmonella variant strain are preferably essentially identical in the biological characteristics except phoN from the parental Salmonella vaccine strain.
  • AphoN Salmonella variant strain differs from the parental Salmonella vaccine strain in one or more characteristics not related to phoN, these alterations may be permanent and, most importantly, may essentially maintain the original immunogenic character of the parental strain which provokes in appropriately vaccinated animals a protective immune response against subsequent Salmonella infection.
  • phoN is inactivated irreversibly by deletion of the nucleic acid fragment encoding the gene phoN by means of genetic engineering.
  • the inactivation process may also include the deletion of accessory nucleic acids from which the transcription of phoN is initiated.
  • the deletion of phoN may be performed in such a manner which suppresses the appearance of novel transcripts.
  • Genetic engineering encompasses any processes of homologous recombination which enable the deletion of the gene phoN in the genome of Salmonellae as indicated herein.
  • the process of homologous recombination should enable the precise deletion of the gene phoN whilst the rest of the genome remained unchanged, which is designated herein as "clean" deletion process.
  • a process of homologous recombination is preferred which is driven by a temporarily co- expressed recombinase, such as the phage ⁇ Red recombinase system as described by Datsenko and Wanner.
  • the Salmonella strain of the present invention may have a reduced motility, e.g. by at least 30%, at least 50% or at least 90%, or/and a reduced biofilm forming capability, e.g. by at least 30%, at least 50% or at least 90%.
  • the AphoN Salmonella strain in particular the live- attenuated AphoN Salmonella strain, more particular DSM 21972, may be a marker vaccine.
  • Live-attenuated AphoN Salmonella marker vaccine strains such as DSM 21972 enable the Differentiation of infected from Vaccinated Animals (DIVA) by serological and/or supplementary bacteriological means.
  • DIVA Vaccinated Animals
  • a polypeptide comprising a Salmonella PhoN polypeptide or/and an immunogenic fragment thereof is used as a serological marker antigen.
  • the serological marker antigen may be any antigen derived from the PhoN polypeptide.
  • the phoN antigen may be a polypeptide comprising the full-length PhoN polypeptide, or comprising any immunogenic portion thereof which has a length of preferably at least 10, more preferably at least 20 and even more preferably at least 30 amino acids.
  • the PhoN polypeptide may be a polypeptide comprising a sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, or a polypeptide comprising a sequence which is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a sequence selected from SEQ ID NO:1 , SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, S
  • the immunogenic portion may have a sequence having at least 70%, at least 80%, at least 90%, at least 95 %, at least 98 %, or at least 99% identical amino acid positions to the sequence of a PhoN polypeptide described herein, wherein % identity is calculated relative to the length of the immunogenic portion. Identity as described herein may be calculated by common algorithms such as BLAST or FASTA. A preferred sequence is SEQ ID NO: 1 derived from strain CLAB_SE 360 (see Figure 1).
  • the serological marker antigen as described herein may be used for the differentiation of infected from vaccinated animal (DIVA) after vaccination with the Salmonella strain of the present invention.
  • a serological marker antigen derived from SEQ ID NO:1 may in particular be used for differentiation of an infected animal from an animal vaccinated with strain DSM 21972.
  • the phoN antigen of the present invention may be prepared by recombinant expression of a phoN nucleic acid, particularly in a recombinant host cell such as E.coli.
  • the phoN antigen may be provided as a frozen stock or as a lyophilisate, optionally together with appropriate preservatives.
  • a serological test system for detecting antibodies directed against a Salmonella phoN antigen, comprising at least one recombinant Salmonella phoN antigen or any immunogenic portion thereof, and optionally further test components.
  • the serological test system may be capable of discrimination of Salmonella infected animals from animals vaccinated by a Salmonella strain of the present invention, in particular a live-attenuated AphoN Salmonella DIVA vaccine, such as CLAB SE404 (DSM 21972).
  • the at least one phoN antigen is an antigen as described herein.
  • the Salmonella phoN antigen preferably comprises the sequence SEQ ID NO:1 or a sequence which is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:1 , wherein identity is calculated relative to the length of SEQ ID NO:1.
  • the antigen serves as a target antigen which specifically detects antibodies in the serum of animals suspected of being infected with Salmonella or may become infected with Salmonella after vaccination. No antibodies are detected by the PhoN target antigen if the serum of animals is used which have been successfully immunized by a Salmonella strain of the present invention, in particular a live-attenuated AphoN Salmonella DIVA vaccine. Detection may be performed in the ELISA format.
  • an additional Salmonella specific antigen is used in the serological test system, such as Salmonella LPS, which detects antibodies induced by both wildtype Salmonella and the Salmonella vaccine strain of the present invention, in particular the live-attenuated AphoN Salmonella DIVA vaccine.
  • phoN nucleic acid encoding a Salmonella antigen as described herein.
  • the phoN nucleic acid comprises a sequence encoding a PhoN polypeptide or a fragment thereof as described herein, for instance a polypeptide comprising a sequence selected from SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, or a polypeptide comprising a sequence which is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical
  • the phoN nucleic acid may be used for the manufacture of a recombinant Salmonella phoN antigen or any immunogenic portion thereof, e.g. in a host such as E. coli by using an appropriate recombinant DNA vector.
  • the phoN antigen may be an antigen as described herein.
  • the phoN antigen may comprise the sequence SEQ ID NO:1, or a sequence which is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:1 , or any immunogenic portion thereof, as described herein. Identity is calculated relative to the length of SEQ ID NO:1.
  • a further subject of the present invention concerns a bacteriological test system for the differentiation of wildtype Salmonella ssp. and a Salmonella strain of the present invention, such as a live-attenuated AphoN Salmonella DIVA vaccines.
  • This bacteriological test system is completing the official standard methods which regulate the detection of Salmonella in biological samples.
  • the inventive bacteriological test system clarifies whenever Salmonella colonies appear in the standard detection methods whether these are wild- type Salmonella or Salmonella strain of the present invention, such as a live- attenuated AphoN Salmonella. At least one suspicious Salmonella colony is analyzed in order to evaluate whether the genome of the individual Salmonella colonies contains the gene phoN or a fragment thereof. Analysis may be performed by a PCR method, or/and by detection of PhoN activity or/ and a PhoN gene product. A representative number of suspicious Salmonella colonies may be analyzed, for instance at least 5, at least 10, at least 15, or at least 20 colonies.
  • PhoN activity can be measured by transferring aliquots of single colonies into separate vials, such as a well of microtiter plate, which contain a PhoN specific substrate mix where PhoN generates a chromogenic product that can be detected by visual control or by an appropriate device.
  • PhoN is localized in the periplasmic space of Salmonella ssp which allows the use of intact cells for determination of PhoN activity.
  • a suitable substrate may be BCIP.
  • the Salmonella strain of the present invention may be detected by a test according to ISO 6579.
  • ISO 6579 is included herein by reference.
  • PhoN activity may be detected by the chromogenic substrate BCIP.
  • Fig. 1 Similarities of PhoN proteins between various Salmonella enterica enterica serovars.
  • Fig. 2 The genomic regions of phoN of Salmonella enterica enterica serovars.
  • Figure 3 illustrates the strategy for the preparation of phoN deletion mutant of live-attenuated Salmonella enterica enterica Enteritidis vaccine strain Salmovac SE using replacement recombination as described by Datsenko and Wanner.
  • the genomic region of S. Enteritidis strain P125109 is exemplarily shown encompassing the phoN locus which is identical to S. Enteritidis vaccine strain Salmovac SE.
  • the genomic region starts at nucleotide (nt) 4.419.410 of the sequence NC_011294.1 which is deposited at the NCBI (National Center for Biotechnology Information) data base (http://www.ncbi.nlm.nih.gov/genomes).
  • ORF open-reading-frame
  • Figure 3A exemplarily illustrates the boundary (solid vertical lines) of the deletion region which comprises the gene phoN.
  • Figure 3B illustrates the ORFs within the original genomic region after replacement of phoN. Three of the original ORFs (ORF1-3) become extended by the recombination process (open arrow).
  • FIG 4 illustrates reverse transcriptase PCR (RT-PCR) analyses within the genomic region of a phoN mutant strain prepared from S. Enteritidis vaccine strain Salmovac SE by replacement recombination as outlined in Figure 3.
  • RT-PCR reverse transcriptase PCR
  • the FRT-site forms a dyad structure of high stability (-17 kcal/mol). It is suggested that the FRT-site actually acts as a transcriptional terminator which suppresses the expression of the ORFs 1-3 beyond the replacement fragment.
  • the primers for the RT-PCR are conceived to detect transcripts which either pass through the replacement fragment (1) or which cover the region in front of the FRT-site (2).
  • Figure 4B shows agarose gel electrophoresis of the RT- PCR products obtained from RNA preparations of S. Enteritidis AphoN vaccine strain which have been treated with reverse transcriptase (RNA) or remained untreated (DNA) before PCR. The data reveal pure RNA probes.
  • RNA reverse transcriptase
  • DNA untreated
  • the virulence of wild type S. Enteritidis strain is compared with live- attenuated S. Enteritidis vaccine strain Salmovac SE and AphoN mutant strain CLAB_SE404.
  • the relative virulence of the various Salmonella strains was assessed by determining the survival rate of Salmonella in MDCK cells within a 24 hours period. The cells were infected with wild type S. Enteritidis strain at an MOI of 10. Both live-attenuated S. Enteritidis vaccine strains were administered at an MOI of 100. After an infection period of 2 hours, excess bacteria in the culture medium were removed by washing. Additionally gentamycin [25 ⁇ g/mL] was added in order to suppress extracellular Salmonella. After 24h cultivation of infected cells under appropriate conditions, the number of intra-cellular Salmonella was determined by lysis of the MDCK cells in PBS containing 1 % Triton-X100.
  • CLAB_SE404 is a non- motile variant of different AphoN mutant clones which have been prepared from live-attenuated S. Enteritidis vaccine strain Salmovac SE as described in the legend to Figure 3. The data indicate reduced virulence of CLAB_SE404 compared to the progenitor strain Salmovac SE.
  • CLAB_SE441 is a motile variant of S. Enteritidis ⁇ phoN [ade/ his] " .
  • CLAB_SE404 is a non-motile variant of S. Enteritidis ⁇ phoN [ade/his] " .
  • White Leghorn chicks which were vaccinated twice with CLAB_SE404, as described in the legend to Figure 6, received an oral challenge infection with 1-2x 10 8 CFU of wild type S. Enteritidis (SE 147N). The challenge infection was administered 21 days after booster vaccination and was analyzed for further 14 days. As a control, na ⁇ ve White Leghorn chicks were infected at the same age of 42 days.
  • Figure 8A exemplarily illustrates parallel plating of wild-type Salmonella Typhimurium and Enteritidis, respectively, on XLT4 agar plates and on LB- agar plates supplemented with the chromogenic phosphatase substrate BCIP [80 ⁇ g/mL]. Wild-type Salmonellae Typhimurium and Enteritidis generally appear on XLD/XLT4 agar plates as black colored colonies and on BCIP LB-agar plates (PhoN-DWA test) as blue-green colored colonies.
  • FIG 8B the parallel plating of the live attenuated Salmonella Enteritidis AphoN vaccine strain CLAB_SE404 is shown.
  • the AphoN Salmonella vaccine strain appears as black-colored colonies on Salmonella specific XLD/XLT4 agar plates but remained uncolored on BCIP LB-agar plates. This finding is surprising, since it is known that Salmonella expresses several enzymes with phosphatase activity. It is concluded that inactivation of the phoN gene is sufficient to prevent the chromogenic phosphate reaction described herein.
  • the outlined testing allows clear differentiation of infected from vaccinated animals within the standard Salmonella test set-up using live-attenuated phoN-DIVA S. Entertitidis vaccine strain CLAB_SE404.
  • PhoN-ONA antibody test as approved by immunoblot analysis using sera from Sa/mone//a-infected chicks (Inf) and sera from chicks immunized with live-attenuated S. Enteritidis phoN-DNA vaccine strain CLAB_SE404 (Vac).
  • the blots of graph A were prepared with two recombinant variants of Salmonella PhoN, PhoN F pioi and PhoN F p2oi.
  • the purified samples have been separated on 10% Schagger-Jagow PAGE prior blotting.
  • PhoN F pioi covers the primary structure of the original PhoN.
  • PhoN F p2oi has truncated NH2- terminus and amino acids substitutions within the active center of PhoN yielding an inactive PhoN.
  • the immunoblot analyses show IgG-specific immune response using appropriate alkaline phosphatase-conjugated antisera. Molecular weight markers are shown in lane M, corresponding to 43, 34 and 26 kDa, respectively.
  • the PhoN-DIVA antibody test displayed in Fig. 9A has been carried out with sera from chicks immunized twice with live-attenuated S. Enteritidis phoN- DIVA vaccine strain CLAB_SE404 (Vac) and sera from na ⁇ ve animals infected with virulent S. Enteritidis strain SE 147N (Inf).
  • the antibodies of the Inf-group bind to both variant PhoN antigens.
  • the Vac-group does not produce PhoN-specific antibodies.
  • Fig. 9B the IgG-titer against S. Enteritidis lysate is illustrated as determined in an ELISA using sera of both animal groups at different times of infection.
  • IgG-titer was determined before (0) and after challenge infection, at days 7 and 28 post infection.
  • the IgG-titer was determined in the same manner.
  • CLAB_SE360 is a variant of the vaccine strain Salmovac SE (Springer et al., 2000, Berl. Munch. Tier GmbHl. Wschr. 113, 246-252). Non-identical amino acids within the primary structure of the various PhoN proteins are highlighted by color.
  • phoN genomic regions are shown in Fig. 2 as follows:
  • the gene phoN has been removed by genetic engineering from the genome of a Salmonella Enteritidis strain which originally derived from a variant of the live-attenuated Salmonella Enteritidis vaccine strain Salmovac SE. More detailed analyses surprisingly showed differences in the population of the AphoN Salmonella Enteritidis vaccine strain variants. Some few AphoN vaccine strain variants have motile activity which is at least 30% of the progenitor strain and the other AphoN vaccine strain variants. In addition, the AphoN vaccine strain variants of reduced motility have reduced capability to form biofilm which, again, is different from the progenitor strain and the other AphoN variants.
  • AphoN Salmonella Enteritidis variants investigated are auxotroph for adenine and histidine and express complex lipopolysaccharide (LPS). They do not contain any of the known virulence plasmids. Thus, all AphoN Salmonella Enteritidis variants include the relevant characteristics of Salmovac SE which has been approved for vaccination laying hens in Germany.
  • CLAB SE404 A single variant, CLAB SE404, has been selected from the population of the AphoN Salmonella Enteritidis variants which have reduced motility and biofilm capability. Further analyses of CLAB SE404 revealed that these additionally identified characteristics are stable beyond 150 generations.
  • strain CLAB SE404 has been deposited under the Budapest Treaty on 10 November 2008 at the DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Inhoffenstra ⁇ e 7 B, D-38124 Braunschweig under deposit number DSM 21972.
  • the virulence of the Salmonella vaccine strains has been assessed by in vitro and in vivo experiments. Quantitative infection of MDCK-cells clearly showed that CLAB SE404 is less virulent in MDCK-cells than the progenitor strain and the motile AphoN Salmonella Enteritidis variants.
  • CLAB SE404 is less virulent in MDCK-cells than the progenitor strain and the motile AphoN Salmonella Enteritidis variants.
  • One-day-old chickens were orally inoculated with either CLAB SE404 or a single variant of the motile AphoN Salmonella Enteritidis group. Afterwards the presence of Salmonella in the various tissues of the vaccinated animals was determined by bacteriological means. The data reveal similar amount of Salmonella in liver and spleen in both animals groups 7 days after vaccination.
  • CLAB SE404 Thereafter the amount of CLAB SE404 declines in the liver and in the spleen but it remained high in the organs of the animals which received the motile AphoN Salmonella Enteritidis variant strain. In the cecal tissue similar results were obtained. The data clearly indicate that CLAB SE404 is less virulent than the motile AphoN Salmonella Enteritidis variant. CLAB SE404 disappeared from the tissues and the excrements of vaccinated chickens much earlier than the motile AphoN Salmonella Enteritidis variant.
  • the immunogenicity of the AphoN Salmonella Enteritidis strains has been determined in chickens which were orally vaccinated by either CLAB SE404 or the motile AphoN Salmonella Enteritidis variant at the age of 1 and 21 days.
  • the humoral and mucosal immune response of both animal groups was assessed by ELISA using Salmonella antigens.
  • CLAB SE404 has similar immunogenic efficacy as the motile AphoN Salmonella Enteritidis variant.
  • CLAB SE404 has similar protective efficacy as the motile AphoN Salmonella Enteritidis variant.
  • CLAB SE404 has been identified as a novel live-attenuated Salmonella vaccine for poultry with low shedding and high efficacy which further enables differentiation of infected from vaccinated animals.
  • PhoN-DIVA antibody test is preferentially prepared on the basis of recombinant PhoN.
  • Previous immunoblot analyses with purified recombinant PhoN clearly reveal that animals vaccinated with live-attenuated Salmonella phoN-DIVA vaccine strain do not generate antibodies which bind to the whole protein. It was surprising that no cross-reactive antibodies do exist within sera of animals immunized with phoN-DIVA Salmonella vaccine strain, despite the complexity of the protein PhoN and the broad-spectrum reactivity of the humoral immune response.
  • the recombinant PhoN for PhoN-DIVA antibody test may be prepared with high purity. Any impurities may be detected by the broad-spectrum antibodies of livestock immunized with PhoN-DIVA Salmonella vaccine and thus cause false results in the PhoN-DIVA antibody test.
  • PhoN The preparation of pure PhoN may be facilitated by extending the primary structure of PhoN with an extra polypeptide fragment that allows highly stringent purification conditions.
  • a series of histidine (His-tag) is introduced either at the amino terminus or at the carboxy terminus of PhoN.
  • His-tag a series of histidine
  • another protein domain may be introduced between the His-tag and the PhoN structure which is specifically recognized by an endopeptidase, e.g. thrombin, which allows the removal of the His-tag.
  • endopeptidase e.g. thrombin
  • the fusion proteins of PhoN can be prepared in Escherichia coli by conventional expression vector, e.g. pET15b and by applying standard purification protocol as indicated by the supplier, e.g. Novagen.
  • Figures 10-12 disclose the maps of the used expression plasmids, the DNA and the amino acid sequences of the exemplarily prepared PhoN fusion proteins, PhoN F pioi and PhoN F p2oi.
  • PhoN-DW/A antibody test is applied whenever chicken become vaccinated with live-attenuated Salmonella phoN-DIVA vaccine strain.
  • the serological PhoN-DIVA test system comprises the recombinant protein PhoN, e.g. PhoN F pioi or PhoN F p 2 oi, and another Salmonella specific antigen.
  • the Salmonella specific antigen is provided by a commercial test kit which detects Salmonella specific antibodies in chicken, e.g. provided by Idexx Laboratories Inc. (Flockchek) or by Labor Diagnostik GmbH für (Flocktype Salmonella) or by Biochek and other companies. This test set-up proves whether Salmonella specific immune response appears after vaccination. Additionally, it proves that no wild-type Salmonella was involved which is indicated by negative reaction with recombinant protein PhoN in the P/70 ⁇ /-DIVA antibody test.
  • the commercial test kits for the detection of Salmonella specific antibodies are prepared as an indirect ELISA in microtiter plates.
  • the Sa/mone//a-specific antigen or antigen mix is already bound to the vials of the microtiter plate or must be coupled later on using an aliquot of a stock solution.
  • the purified PhoN e.g. PhoN F p 2 oi
  • PhoN F p 2 oi is preferentially provided as a frozen stock solution or as a lyophilisate with appropriate preservative agents.
  • the ELISA for the detection of PhoN-specific antibodies is performed according to standard protocol as described elsewhere, e.g. by E. Harlow and D. Lane in Antibodies. A Laboratory Manual. 1/1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

La présente invention concerne une souche de salmonelle appropriée en tant que vaccin marqueur ayant un gène inactivé.
PCT/EP2009/065571 2008-11-20 2009-11-20 Vaccin marqueur de la salmonelle WO2010057985A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0921065A BRPI0921065A2 (pt) 2008-11-20 2009-11-20 vacina marcadora para salmonela
EP09753133A EP2358384A2 (fr) 2008-11-20 2009-11-20 Vaccin marqueur de la salmonelle
MX2011005281A MX2011005281A (es) 2008-11-20 2009-11-20 Vacuna marcadora de salmonella.
JP2011536877A JP2012509075A (ja) 2008-11-20 2009-11-20 サルモネラマーカーワクチン
CN2009801527921A CN102361648A (zh) 2008-11-20 2009-11-20 沙门氏菌标记疫苗
AU2009317211A AU2009317211A1 (en) 2008-11-20 2009-11-20 Salmonella marker vaccine
CA2744251A CA2744251A1 (fr) 2008-11-20 2009-11-20 Vaccin marqueur de la salmonelle
US13/129,844 US20120114698A1 (en) 2008-11-20 2009-11-20 Salmonella marker vaccine
ZA2011/04477A ZA201104477B (en) 2008-11-20 2011-06-17 Salmonella marker vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08020242A EP2189164A1 (fr) 2008-11-20 2008-11-20 Vaccin à marqueur de la salmonelle
EP08020242.7 2008-11-20

Publications (2)

Publication Number Publication Date
WO2010057985A2 true WO2010057985A2 (fr) 2010-05-27
WO2010057985A3 WO2010057985A3 (fr) 2010-07-15

Family

ID=40527918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065571 WO2010057985A2 (fr) 2008-11-20 2009-11-20 Vaccin marqueur de la salmonelle

Country Status (10)

Country Link
US (1) US20120114698A1 (fr)
EP (2) EP2189164A1 (fr)
JP (1) JP2012509075A (fr)
CN (1) CN102361648A (fr)
AU (1) AU2009317211A1 (fr)
BR (1) BRPI0921065A2 (fr)
CA (1) CA2744251A1 (fr)
MX (1) MX2011005281A (fr)
WO (1) WO2010057985A2 (fr)
ZA (1) ZA201104477B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011092185A1 (fr) * 2010-01-28 2011-08-04 Universiteit Gent Vaccin contre salmonella

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20131048A3 (cs) * 2013-12-20 2015-04-22 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Použití antigenů Salmonella enterica ssp. enterica sérovar Typhimurium pro sérologické odlišení infikovaných a vakcinovaných prasat
CN106754535B (zh) * 2016-12-31 2020-07-24 山东信得科技股份有限公司 一种重组弱毒肠炎沙门氏菌
CN112546210A (zh) * 2020-12-15 2021-03-26 南京农业大学 一种沙门菌灭活疫苗的制备方法及应用
JP7550454B2 (ja) 2021-10-21 2024-09-13 国立研究開発法人農業・食品産業技術総合研究機構 ＢａｍＡタンパク質を利用したサルモネラ属菌感染の検出方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442517B2 (en) * 2001-10-31 2008-10-28 Lawrence Livermore National Security, Llc Method for the detection of Salmonella enterica serovar Enteritidis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUCHS ET AL., PLASMID, vol. 55, 2006, pages 39 - 49

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011092185A1 (fr) * 2010-01-28 2011-08-04 Universiteit Gent Vaccin contre salmonella

Also Published As

Publication number Publication date
US20120114698A1 (en) 2012-05-10
AU2009317211A1 (en) 2011-07-07
CA2744251A1 (fr) 2010-05-27
EP2189164A1 (fr) 2010-05-26
BRPI0921065A2 (pt) 2015-12-15
WO2010057985A3 (fr) 2010-07-15
CN102361648A (zh) 2012-02-22
EP2358384A2 (fr) 2011-08-24
MX2011005281A (es) 2012-04-10
JP2012509075A (ja) 2012-04-19
ZA201104477B (en) 2012-02-29

Similar Documents

Publication Publication Date Title
Shivachandra et al. A review of hemorrhagic septicemia in cattle and buffalo
Monreal et al. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model
RU2556813C2 (ru) Живые аттенуированные вакцины
Tidhar et al. The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague
AU2016222520B2 (en) Attenuated Streptococcus suis vaccines and methods of making and use thereof
RU2465331C2 (ru) Бактериальные факторы вирулентности и варианты их применения
EP3488862B1 (fr) Compositions immunologiques contenant des souches de histophilus somni atténuées
JP2009531029A (ja) 弱毒化サルモネラ生ワクチン
US20120114698A1 (en) Salmonella marker vaccine
RU2252224C2 (ru) Пептид со свойствами антигена neisseria meningitidis, кодирующий его полинуклеотид, вакцина для лечения или предотвращения заболеваний или состояний, вызванных neisseria meningitidis, (варианты), антитело, связывающееся с указанным пептидом
Singh et al. Molecular heterogeneity of plpE gene in Indian isolates of Pasteurella multocida and expression of recombinant PlpE in vaccine strain of P. multocida serotype B: 2
Kang et al. Safety and protective efficacy of Salmonella Pullorum spiC and rfaH deletion rough mutant as a live attenuated DIVA vaccine candidate
CN110642927A (zh) 一种蛋白在制备预防化脓隐秘杆菌感染的药物中的应用
CA2719041C (fr) Compositions, procedes et kits
Du et al. Two novel cross‑protective antigens for bovine Pasteurella multocida
Wang et al. Identification of Subunits for Novel Universal Vaccines against Three Predominant Serogroups and the Emerging O145 among Avian Pathogenic Escherichia coli by Pan-RV Pipeline
US20110287520A1 (en) Salmonella marker vaccine
MX2010009516A (es) Secuencias novedosas de brachyspira, composiciones inmunogenicas, metodos para la preparacion y usos de las mismas.
Walters Characterization of atypical hemolytic Ornithobacterium rhinotracheale Isolates and comparison with the normal non-hemolytic phenotype
김남형 Evolutionary genetics and immunological characterization of Salmonella enterica subsp. enterica serovar Gallinarum biovar Gallinarum
Meng et al. A Live Attenuated DIVA Vaccine Induce Protection Against Listeria monocytogenes Challenge in Sheep
Tidhar et al. The NlpD Lipoprotein Is a Novel Yersinia pestis Virulence Factor Essential for the
US20140248272A1 (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
Zhang Proteomics analysis of outer membrane proteins of leptospira interrogans
San Román Aberasturi et al. The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980152792.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09753133

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2744251

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011536877

Country of ref document: JP

Ref document number: MX/A/2011/005281

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009317211

Country of ref document: AU

Ref document number: 2505/KOLNP/2011

Country of ref document: IN

Ref document number: 2009753133

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011124944

Country of ref document: RU

Ref document number: A201107671

Country of ref document: UA

Ref document number: 11076498

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2009317211

Country of ref document: AU

Date of ref document: 20091120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13129844

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0921065

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110520